MX2018012999A - Composicion de extrusion fundida en caliente que usa un excipiente compresible directo como plastificante. - Google Patents

Composicion de extrusion fundida en caliente que usa un excipiente compresible directo como plastificante.

Info

Publication number
MX2018012999A
MX2018012999A MX2018012999A MX2018012999A MX2018012999A MX 2018012999 A MX2018012999 A MX 2018012999A MX 2018012999 A MX2018012999 A MX 2018012999A MX 2018012999 A MX2018012999 A MX 2018012999A MX 2018012999 A MX2018012999 A MX 2018012999A
Authority
MX
Mexico
Prior art keywords
plasticizer
melt extrusion
hot melt
direct compressible
compressible excipient
Prior art date
Application number
MX2018012999A
Other languages
English (en)
Inventor
Lubda Dieter
Zheng Mengyao
Giuseppe Elia Alessandro
Di Gallo Nicole
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of MX2018012999A publication Critical patent/MX2018012999A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/04—Oxygen-containing compounds
    • C08K5/05—Alcohols; Metal alcoholates
    • C08K5/053—Polyhydroxylic alcohols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08K—Use of inorganic or non-macromolecular organic substances as compounding ingredients
    • C08K5/00—Use of organic ingredients
    • C08K5/0008—Organic ingredients according to more than one of the "one dot" groups of C08K5/01 - C08K5/59
    • C08K5/0016—Plasticisers
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
    • C08L29/00—Compositions of homopolymers or copolymers of compounds having one or more unsaturated aliphatic radicals, each having only one carbon-to-carbon double bond, and at least one being terminated by an alcohol, ether, aldehydo, ketonic, acetal or ketal radical; Compositions of hydrolysed polymers of esters of unsaturated alcohols with saturated carboxylic acids; Compositions of derivatives of such polymers
    • C08L29/02—Homopolymers or copolymers of unsaturated alcohols
    • C08L29/04—Polyvinyl alcohol; Partially hydrolysed homopolymers or copolymers of esters of unsaturated alcohols with saturated carboxylic acids

Abstract

La presente invención se relaciona con el uso de sorbitol secado por atomización, tal como Parteck(r) SI, como plastificante para composiciones que contienen un polímero procesadas por extrusión fundida en (caliente). Debido a sus propiedades mejoradas logradas por su proceso de manufacturación especial (secado por atomización), este excipiente compresible directo muestra más beneficios adicionales que la misma sustancia en el estado cristalino.
MX2018012999A 2016-05-13 2017-05-10 Composicion de extrusion fundida en caliente que usa un excipiente compresible directo como plastificante. MX2018012999A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16169693 2016-05-13
PCT/EP2017/061126 WO2017194576A1 (en) 2016-05-13 2017-05-10 Hot melt extrusion composition using direct compressible excipient as plasticizer

Publications (1)

Publication Number Publication Date
MX2018012999A true MX2018012999A (es) 2019-01-28

Family

ID=56134085

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018012999A MX2018012999A (es) 2016-05-13 2017-05-10 Composicion de extrusion fundida en caliente que usa un excipiente compresible directo como plastificante.

Country Status (12)

Country Link
US (1) US11510986B2 (es)
EP (1) EP3454836A1 (es)
JP (1) JP6955517B2 (es)
KR (1) KR102358069B1 (es)
CN (1) CN109152739B (es)
BR (1) BR112018071673B1 (es)
CA (1) CA3023800A1 (es)
IL (1) IL262908B (es)
MX (1) MX2018012999A (es)
PH (1) PH12018502055A1 (es)
SG (1) SG11201809973YA (es)
WO (1) WO2017194576A1 (es)

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2542346B2 (ja) 1987-05-30 1996-10-09 日本合成化学工業株式会社 高重合度ポリビニルアルコ−ルの製造法
JP2577698B2 (ja) * 1993-08-05 1997-02-05 信道 中野 流動性の高いソルビトール粉末の製造方法
DE19617487A1 (de) * 1996-05-02 1997-11-06 Merck Patent Gmbh Geschmacksverbesserung von Arzneimittelwirkstoffen
JP4783278B2 (ja) * 2003-02-03 2011-09-28 ノバルティス アーゲー 医薬製剤
EP1778612A1 (en) * 2004-06-17 2007-05-02 Cargill, Incorporated Steam agglomeration of polyols
CN101516339B (zh) * 2006-08-16 2012-06-13 诺瓦提斯公司 制备高度结晶的治疗化合物的固体分散体的方法
EP2293774B1 (de) * 2008-06-20 2019-01-16 Merck Patent GmbH Direkt verpressbare polyolkombination
GB0909680D0 (en) 2009-06-05 2009-07-22 Euro Celtique Sa Dosage form
US20120114717A1 (en) * 2009-07-10 2012-05-10 Merck Patent Gesellschaft Mit Beschrankter Haftung Tableting agent having a low water content, and method for the production thereof
WO2011003603A2 (de) * 2009-07-10 2011-01-13 Merck Patent Gmbh Zusammensetzung für die tablettenherstellung und verfahren zu deren herstellung
GB201020895D0 (en) * 2010-12-09 2011-01-26 Euro Celtique Sa Dosage form
CN102204868B (zh) * 2011-05-18 2014-01-22 北京化工大学 采用多元辅料制备吲哚美辛速释制剂的热熔挤出工艺
RU2013155713A (ru) * 2011-07-06 2015-08-20 Профибрикс Бв Составы для лечения ран
US20130071476A1 (en) * 2011-08-19 2013-03-21 Subraman Rao Cherukuri Rapid Melt Controlled Release Taste-Masked Compositions
CN105012242A (zh) * 2015-07-21 2015-11-04 南京中医药大学 一种厚朴酚或和厚朴酚或两者混合物固体分散体及其热熔挤出制备方法

Also Published As

Publication number Publication date
CN109152739A (zh) 2019-01-04
SG11201809973YA (en) 2018-12-28
BR112018071673B1 (pt) 2024-02-27
JP6955517B2 (ja) 2021-10-27
JP2019515006A (ja) 2019-06-06
US20200254098A1 (en) 2020-08-13
CN109152739B (zh) 2022-09-30
US11510986B2 (en) 2022-11-29
KR20190008556A (ko) 2019-01-24
PH12018502055A1 (en) 2019-06-24
BR112018071673A2 (pt) 2019-02-19
CA3023800A1 (en) 2017-11-16
WO2017194576A1 (en) 2017-11-16
EP3454836A1 (en) 2019-03-20
IL262908B (en) 2022-04-01
IL262908A (en) 2018-12-31
KR102358069B1 (ko) 2022-02-03

Similar Documents

Publication Publication Date Title
PH12019500393A1 (en) Substituted pyrrolizine compounds and uses thereof
PH12017501413A1 (en) Substituted nucleoside derivatives useful as anticancer agents
MX2018012016A (es) Compuestos biciclicos.
MX2018012085A (es) Compuestos agonistas de gpr119 y metodo para tratar enfermedades y afecciones mediado a traves de gpr119.
WO2017175068A8 (en) Thiazolopyridine derivatives as gpr119 agonists
NZ716840A (en) Combination formulation of two antiviral compounds
MX2017009505A (es) Derivados de 9h-pirrolo-dipiridina.
PH12017501539A1 (en) Disacetoxytubulysin h and analogs thereof
MY185749A (en) Polypropylene composition for a layer element
MX2019008798A (es) Nueva formulacion.
MX2017016619A (es) Derivados de pirimidina como inhibidores de tirosina cinasa de bruton (btk) y usos de los mismos.
WO2016013030A3 (en) Hydroxysteroid compounds, their intermediates, process of preparation, composition and uses thereof
WO2016092561A3 (en) Novel polymorphs of ivacaftor, process for its preparation and pharmaceutical composition thereof
EP3310821A4 (en) COMPOSITIONS CONTAINING 1,1-DISUBSTITUTED ALKENIC COMPOUNDS FOR THE PREPARATION OF POLYMERS HAVING ENHANCED VITREOUS TRANSITION TEMPERATURES
WO2015029074A3 (en) Compositions of eltrombopag
WO2016166720A3 (en) Polymorphs of afatinib and its salts and process for the preparation of quinazolinyl derivatives
MX2020002123A (es) Sales de ribociclib y formas en estado sólido de las mismas.
WO2017008136A3 (en) Flourinated cbd compounds, compositions and uses thereof
WO2014197197A8 (en) High temperature geomembrane liners and master batch compositions
PH12018500151A1 (en) Compound targeting il-23a and b-cell activating factor (baff) and uses thereof
EP3288636A4 (en) COMPOSITIONS FOR THE TREATMENT OF EPISTAXIS
EP3331939A4 (en) METHODS OF PRODUCING HIGH VISCOSITY COMPOUNDS AS RHEOLOGY MODIFIERS, AND COMPOSITIONS PRODUCED THEREBY
MY182134A (en) Substituted pyridyl-cycloalkyl-carboxylic acids, compositions containing them and uses thereof
WO2015052568A3 (en) Solid forms of curcumin and derivatives thereof
PH12018502055A1 (en) Hot melt extrusion composition using direct compressible excipient as plasticizer